BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 24938292)

  • 1. Feasibility of using the Multinational Association of Supportive Care in Cancer Antiemesis Tool for assessment of chemotherapy-induced nausea and vomiting at the Tom Baker Cancer Centre.
    Warr JK; Chambers CR; Cusano FL; Cuthbert CA; Mah MS
    J Oncol Pharm Pract; 2015 Oct; 21(5):348-57. PubMed ID: 24938292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool.
    Matsuda Y; Okita K; Furuhata T; Kutomi G; Yamashita K; Sato Y; Takimoto R; Hirata K
    Support Care Cancer; 2015 Nov; 23(11):3331-9. PubMed ID: 26003425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Quantification of Chemotherapy-Induced Nausea and Emesis between the Common Terminology Criteria for Adverse Events and the Multinational Association of Supportive Care in Cancer Antiemesis Tool.
    Uchida M; Nakamura T; Shima T; Yoshimoto G; Kato K; Hosohata K; Miyamoto T; Akashi K
    Biol Pharm Bull; 2018; 41(11):1667-1671. PubMed ID: 30381666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
    Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
    J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of chemotherapy-induced nausea and vomiting(CINV)using MASCC antiemesis tool].
    Yamaguchi M; Ogawa T; Watanabe M; Anami S; Kamigaki S; Nishikawa N; Ono T; Furukawa H
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1691-6. PubMed ID: 19838029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy.
    Smit T; Kotze I; du Plessis J
    Ann Palliat Med; 2021 Mar; 10(3):2679-2686. PubMed ID: 33549001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms.
    Rha SY; Song SK; Lee CE; Park Y; Lee J
    Support Care Cancer; 2016 Nov; 24(11):4559-66. PubMed ID: 27278273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An assessment tool for chemotherapy-induced nausea and vomiting and intervention outcomes].
    Aimono Y; Suzuki S; Nemoto M; Saito Y; Aoyama Y; Joko F; Maruyama T; Kamoshida T
    Gan To Kagaku Ryoho; 2013 Dec; 40(13):2551-4. PubMed ID: 24335368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative evaluation of 2 antiemesis tools for the prevention of chemotherapy-induced nausea and vomiting].
    Murata H; Teramoto Y; Kawashita M; Oi M; Kitaguchi T; Sasahira E; Masuda A; Satake Y; Enomoto S; Komai C; Udo M; Komuta K; Yamamoto K
    Gan To Kagaku Ryoho; 2014 Mar; 41(3):341-5. PubMed ID: 24743280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
    Shih V; Wan HS; Chan A
    Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychometric assessment of the Chinese version of the MASCC Antiemesis Tool (MAT) for measuring chemotherapy-induced nausea and vomiting.
    Tan JY; Suen LK; Molassiotis A
    Support Care Cancer; 2016 Sep; 24(9):3729-37. PubMed ID: 27039204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.
    Gilmore JW; Peacock NW; Gu A; Szabo S; Rammage M; Sharpe J; Haislip ST; Perry T; Boozan TL; Meador K; Cao X; Burke TA
    J Oncol Pract; 2014 Jan; 10(1):68-74. PubMed ID: 24065402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
    Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries.
    Hsieh RK; Chan A; Kim HK; Yu S; Kim JG; Lee MA; Dalén J; Jung H; Liu YP; Burke TA; Keefe DM
    Support Care Cancer; 2015 Jan; 23(1):263-72. PubMed ID: 25120009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Perceptual gap between oncologists/oncology nurses and patients in the management and impact of chemotherapy/radiotherapy-induced nausea and vomiting: French results of the GAP survey].
    Morin S; Leurs I; Bousquet MN; Scotté F
    Bull Cancer; 2016 May; 103(5):469-77. PubMed ID: 27015797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric assessment of the Persian version of short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemetic tool.
    Eghbali M; Negarandeh R; Ebadi A; Bandari R; Mohammadzadeh F
    Support Care Cancer; 2020 Sep; 28(9):4353-4359. PubMed ID: 31907650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool.
    Molassiotis A; Coventry PA; Stricker CT; Clements C; Eaby B; Velders L; Rittenberg C; Gralla RJ
    J Pain Symptom Manage; 2007 Aug; 34(2):148-59. PubMed ID: 17509816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
    Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
    Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey.
    Vidall C; Fernández-Ortega P; Cortinovis D; Jahn P; Amlani B; Scotté F
    Support Care Cancer; 2015 Nov; 23(11):3297-305. PubMed ID: 25953380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.